Skip to content

Clinical trials

Observational Chlamydia Infections trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Chlamydia Infections Phase: Observational Clear all

36 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20041
20052
20061
20071
20081
20094
20101
20111
20122
20132
20143
20162
20193
20202
20231
20253
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed25
Terminated4
Recruiting3
Withdrawn2
Not yet recruiting1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of California, San Francisco4
University of Pittsburgh4
National Heart, Lung, and Blood Institute (NHLBI)3
Arkansas Children's Hospital Research Institute2
Gen-Probe, Incorporated2
Children's Hospital of Eastern Ontario1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)1
Harold Wiesenfeld1
Henry Ford Health System1
Hospital de Base1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Chlamydia Infections36
Gonorrhea21
Sexually Transmitted Diseases11
Syphilis6
HIV Infections5
Trichomonas Infections5
Acquired Immunodeficiency Syndrome3
Infections3
Mycoplasma Infections3
Stroke3

Trials

Showing 76 to 36 of 36. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.